Repositioning Candidate Details
| Candidate ID: | R1244 |
| Source ID: | DB09213 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Dexibuprofen |
| Synonyms: | (+)-(S)-p-isobutylhydratropic acid; (2S)-2-(4-isobutylphenyl)propanoic acid; (S)-α-methyl-4-(2-methylpropyl)benzeneacetic acid; d-ibuproten; Dexibuprofen |
| Molecular Formula: | C13H18O2 |
| SMILES: | CC(C)CC1=CC=C(C=C1)[C@H](C)C(O)=O |
| Structure: |
|
| DrugBank Description: | Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability . For Metabolism, Enzymes, Carriers, Transporters Sections, refer to . |
| CAS Number: | 51146-56-6 |
| Molecular Weight: | 206.2808 |
| DrugBank Indication: | For more information, refer to . |
| DrugBank Pharmacology: | For more information, refer to . |
| DrugBank MoA: | Like common NSAIDs, dexibuprofen is an active enantiomer of that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX. For more information, refer to . |
| Targets: | Prostaglandin G/H synthase 2 inhibitor; Prostaglandin G/H synthase 1 inhibitor; Apoptosis regulator Bcl-2 negative modulator; Thrombomodulin modulator; Tissue-type plasminogen activator modulator; Fatty acid-binding protein, intestinal binder; Peroxisome proliferator-activated receptor gamma activator; Cystic fibrosis transmembrane conductance regulator inhibitor; Solute carrier family 15 member 1; Peroxisome proliferator-activated receptor alpha; Platelet glycoprotein Ib alpha chain; Protein S100-A7 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T35 | Platelet glycoprotein Ib alpha | GP1BA | inhibitor | Enzyme | P07359 | GP1BA_HUMAN | Details |
| T10 | Caspase-1 | CASP1 | inhibitor | Enzyme | P29466 | CASP1_HUMAN | Details |
| T03 | Peroxisome proliferator-activated receptor alpha | PPARA | agonist | Nuclear hormone receptor | Q07869 | PPARA_HUMAN | Details |
| T05 | Peroxisome proliferator-activated receptor gamma | PPARG | agonist | Nuclear hormone receptor | P37231 | PPARG_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|